A clinical grade cell-based artificial APT, aAPC/mOKT3, for unbiased expansion of CD3+ T lymphocytes

Abstract

Recent clinical results confirm that adoptive cell therapy, whereby expanded antitumor lymphocytes are infused into cancer patients, is a promising new therapy. Standar-dized methods to reproducibly and efficiently expand high quality antitumor lymphocytes in vitro are needed. We and others have successfully used cell-based artificial APCs (aAPCs) in the clinic as an off-the-shelf, standar-dized, and renewable reagent to reliably expand antitumor T cells in vitro for adoptive therapy. Recently, we have reported a genetically engineered novel human cell-based aAPC, aAPC/mOKT3, which expresses a membranous form of anti-CD3 mAb (mOKT3) in conjunction with immunostimulatory molecules, CD80 and CD83. Without requiring allogeneic feeder cells, aAPC/mOKT3 induces the robust expansion of both peripheral and tumor-infiltrating T cells, regardless of HLA-restriction, but not Foxp3 + regulatory T cells or NK cells. Expanded T cells predominantly secreted Th1-type cytokines such as inter-feron-g and IL-2. Unlike anti-CD3/CD28 mAb-coated beads, aAPC/mOKT3 enabled significantly improved CD8 + T cell expansion in part through IL-21 secreted by cocultured CD4 + T cells. To generate a clinical grade ver-sion of this aAPC, the parental cell line K562 was cotrans-fected with five linearized DNA plasmids encoding the light and heavy chains of mOKT3, CD80, CD83, and a puromycin N-acetyl-transferase gene. Simultaneous trans-fection of the 5 plasmids and subsequent drug selection resulted in aAPC/mOKT3 lines with >20% triple positivity (mOKT3, CD80, and CD83). Using a limiting dilution method, >100 candidate clones were established. Based on high expression of all 3 surface molecules, 41 clones were selected for long-term culture and monitoring for stable, high triple expression. After 3 months of continuous culture, 9 clones demonstrated stable expression and had suitable doubling time (24-40 hours). As seen with research grade aAPC/mOKT3, all clones induced the pre-ferential expansion of CD8 + T cells in the presence of CD4 + T cells. Two clones, which consistently induced superior CD8 + T cell proliferation (>1,000 fold within 4 weeks), are lead candidates for selection to generate a master cell bank of clinical grade aAPC/mOKT3. Further criteria for selection include the ability of clones to expand T cells with a non-exhausted, young phenotype without contaminating immunosuppressive cell populations. Ability of expanded T cells to secrete Th1 cytokines and not immunosuppressive cytokines such as IL-10 or TGF-b will be confirmed. Once these data are obtained, a single clone will be chosen to generate a master cell bank and clinical lots for use in future clinical trials.